Clinical trials · Pennsylvania
Pancreatic cancer clinical trials in Pennsylvania
We’re tracking 59 recruiting pancreatic cancer studies with a site in Pennsylvania — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT06244771RecruitingPhase 1/Phase 2
Testing FMC-376 for KRAS G12C mutated solid tumors
This study tests a new targeted pill called FMC-376 for people whose cancer has a specific KRAS G12C mutation. The goal is to see if it can shrink tumors or slow their growth when other treatments have stopped working.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06073431Recruiting
Study on weight loss types in advanced cancer
This study looks at different types of weight loss (cachexia) in people with advanced lung, pancreatic, or colorectal cancer. Researchers want to find patterns to better understand and treat it. You can join even if you haven't lost weight yet.
Danville, PennsylvaniaAges 18 years+ - NCT07307664Recruiting
Increasing genetic testing for cancer patients
This trial aims to increase the use of genetic testing (germline testing) among cancer patients by working with healthcare providers like oncologists and nurses. If you are an oncology care team member treating adults with breast, pancreatic, or colorectal cancer, this study may be for you.
Danville, PennsylvaniaAges Any age - NCT07638410Recruiting
Getting fit before major cancer surgery
This trial tests whether special preparation exercises and wellness support before chemotherapy and major abdominal or pelvic surgery can help you recover better and stay stronger. You'll work with a team including exercise specialists and mental health counselors before your operation.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07199764RecruitingPhase 2
Maintenance therapy using combination immunotherapy for pancreatic cancer
This trial tests a combination of immunotherapy drugs (targeting CD40 and other immune cells) as a maintenance treatment for people with advanced pancreatic cancer that has not grown or has shrunk after initial chemotherapy. The goal is to see if this approach can keep the cancer from progressing longer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06984562Recruiting
Adaptive radiation therapy for advanced pancreatic cancer
This trial tests a new way of giving radiation therapy that adapts to changes in your cancer over time. It is for people with pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05743049Recruiting
Collecting blood markers in pancreatic cancer patients
This study collects samples of substances in your blood to learn more about pancreatic cancer. It may help researchers find better ways to track the disease or understand which patients may benefit from future treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06850623RecruitingPhase 2
Sound wave therapy plus chemo for advanced pancreatic cancer
This trial tests a new treatment that uses sound waves to help chemotherapy reach pancreatic tumors more effectively. It is for people with locally advanced pancreatic cancer that cannot be removed with surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06128551RecruitingPhase 1/Phase 2
Testing two targeted drugs for KRAS G12C advanced cancer
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07812805RecruitingPhase 1
New targeted treatment with imaging for advanced solid tumors
This trial tests a new experimental treatment (SKL35501) that uses a special imaging agent (SKL35502) to find and target a marker called NTSR1 found on some advanced cancers. The goal is to see if this treatment is safe and can help people whose cancer has stopped responding to standard treatments.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06026410RecruitingPhase 1
KO-2806 for advanced solid tumors
This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07594067RecruitingPhase 1
TCR T cells for KRAS-mutated cancers
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06271291Recruiting
Pancreatic Cancer Detection Study for High-Risk People
This study looks for people at high risk for pancreatic cancer, either because of family history, certain genetic mutations, or concerning pancreatic cysts. Researchers want to follow you over time to find cancer early, when it's easier to treat.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06710756RecruitingPhase 1/Phase 2
Lead-212 therapy for solid tumors
This trial tests a new radioactive drug, Lead-212 PSV359, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to find and attack cancer cells.
Pittsburgh, PennsylvaniaAges 18–90 - NCT00912717Recruiting
Study of pancreas cancer risk in families and environment
This study looks at factors in the family and the environment that may be linked to pancreatic cancer. It includes people with pancreatic cancer and several types of pancreas-related conditions, as well as some healthy volunteers, and may help researchers understand who is at higher risk.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06651580Recruiting
Gene study for kids with pancreas problems
This study collects samples like blood or tissue from children with pancreatitis to look for gene changes that might raise their risk. It helps doctors learn more about why some children get pancreas inflammation.
Philadelphia, PennsylvaniaAges Up to 17 years - NCT02471170Enrolling by invitation
Taking blood samples for pancreatic and related cancer research
This study asks people receiving care at the University of Pennsylvania Hospital to provide samples that can help researchers study tumor material. If you have pancreatic disease—or you’re getting care for something else (like a routine colonoscopy)—your samples may be used to compare findings and improve future research.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05482893RecruitingPhase 1/Phase 2
Study of spevatamig for advanced gastrointestinal cancers
This trial tests a new drug called spevatamig (PT886) alone or with other treatments for advanced stomach, gastric, pancreatic, bile duct, or colorectal cancers. The goal is to see if it helps slow or stop cancer growth.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04858334RecruitingPhase 2
Olaparib after pancreatic cancer surgery for BRCA or PALB2 mutations
This trial studies whether olaparib (a targeted cancer medicine) can help prevent pancreatic cancer from coming back after surgery in people with BRCA1, BRCA2, or PALB2 mutations. You would get olaparib or a placebo (inactive pill) and be closely followed to see if recurrence is reduced.
Bryn Mawr, PennsylvaniaAges 18 years+ - NCT06605404Recruiting
Pan-tumor study of a blood test after cancer surgery
This study is testing a new blood test that looks for leftover cancer cells after surgery. It is for people with different types of solid tumors who are planning to have surgery to cure their cancer. The goal is to see if the test can help guide future treatment decisions.
Lancaster, PennsylvaniaAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Pittsburgh, PennsylvaniaAges 18 years+
Pancreatic cancer trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting pancreatic cancer studies listed above.
- Fox Chase Cancer Center · 3 studies
- Allegheny Health Network · 2 studies
- Research Site · 2 studies
- University of Pennsylvania · 2 studies
- University of Pittsburgh · 2 studies
- UPMC Hillman Cancer Center · 2 studies
- Abramson Cancer Center at University of Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania
What taking part in a pancreatic cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Pancreatic cancer trials in other states
Common questions
- Are there pancreatic cancer clinical trials in Pennsylvania?
- Yes. We're currently tracking 59 recruiting pancreatic cancer studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a pancreatic cancer study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a pancreatic cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New pancreatic cancer studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.